Biopharma, a biopharmaceutical company based in Kyiv, plans to triple the number of its plasma centers to 30 by 2027, according to the company’s president Konstantin Efimenko.
“We plan to increase the number of plasma centers. Currently, there are 10 of them, but by 2027 we want to increase their number to 30,” he said during the forum “Dialogues on Sustainability. How Business Develops in Times of War” forum in Kyiv on Thursday.
He also said that since the beginning of the full-scale invasion, the company “has not stopped working for almost a single day.”
In particular, in March 2022, Biopharma built a complex of diesel generator stations with a total capacity of 2 mW and purchased four 10 cubic meters of fuel tanks, built bomb shelters at the plant and in its office in Kyiv.
As reported, in 2020, Biopharma announced plans to invest $20-23 million in the development of a network of plasma centers by 2025 and build plasma and blood centers in every regional center of Ukraine.
